Phase III clinical trial of Zhongzhu 1018, an anticancer drug jointly developed by Qianjiang pharmaceutical and TnI

In October 2012, Qianjiang pharmaceutical, a subsidiary of China Pearl holdings, signed a cooperation agreement with TnI Biotechnology Co., Ltd (US) to jointly develop preclinical research on blood, bone marrow hematopoietic system cancer and cancer patients' immune recovery anticancer drugs In order to avoid risks, the two sides agreed to determine further cooperation after the US entered the third phase of clinical practice Reporters yesterday learned from people close to the company that, in principle, after TnI was allowed to enter phase III clinic, China and the United States will further promote phase III clinic in China In view of the cooperation agreement between China food and Drug Administration and FDA, the drugs approved by the US side to enter phase III clinical will enjoy a green channel in China At present, the cooperation project between the two sides in China is still in the laboratory stage Previously, it was rumoured in the market that once TnI bio obtained the approval of FDA's third phase plan for pancreatic cancer, TnI bio will give the final budget to Hubei Qianjiang pharmaceutical Under the agreement of both parties, Hubei Qianjiang pharmaceutical will be responsible for the preparation of the fund It is estimated that the cost of the third phase plan will be US $30 million to US $40 million, and Hubei Qianjiang pharmaceutical will also get the exclusive franchise of the drug in China It is understood that TnI company has possessed the new drugs (including the intellectual property rights, patent technology and license currently possessed by "Zhongzhu 1018") for the treatment of cancer in blood and bone marrow hematopoietic system and the immune recovery of cancer patients, and obtained the results in preclinical stage, and has conducted preclinical research with Qianjiang pharmaceutical Zhongzhu holding said that the purpose of holding hands with TnI of the United States is to let Qianjiang pharmaceutical obtain the exclusive license of "Zhongzhu 1018" technology in China, and obtain the new drug certificate and production approval of "Zhongzhu 1018", a national first-class chemical, issued by China food and drug administration At the same time, the cooperation between the two sides is also conducive to strengthening the research and development of drugs and increasing the drug reserves of Qianjiang pharmaceutical.